Aspergillus fumigatus (ATCC 13073), Lung Infection Model, LD90-100
CONTACT CUSTOMER SERVICE
ADD TO FAVORITES
ADD TO PANEL
OVERVIEW
DOCUMENTS/REFERENCES
BIOLOGICAL INFORMATION
BACKGROUND INFORMATION
This model assesses the efficacy of antifungal test articles in a lethal pulmonary aspergillosis, performed with neutropenic BALB/c mice. It may be used for evaluating small molecules and biologics.
SPECIES
Aspergillus fumigatus
ORGANISM
Fungi
INCUBATION CONDITIONS
Aerobic
SOURCE
STRAIN SOURCE
American Type Culture Collection (ATCC)
ASSAY INFORMATION
ASSAY TYPE
In Vivo
TESTING INFORMATION
PROCEDURE SUMMARY
Groups of 10 neutropenic mice are used. Each animal is inoculated with an intranasal administered lethal (LD90-100) dose of pathogen. Test substance and vehicle are administered at specified time points following infection. Mortality is recorded daily during the following 14 days. Prevention of mortality in 50 percent or more (>50%) of the animals indicates significant activity. The Minimum Effective Dose (MED) is defined as the dose that results in survival of 50% (or more) of the test animals.
CRITERIA FOR SIGNIFICANCE
Significant difference is determined at ≥ 50% or P < 0.05
TURNAROUND TIME
STANDARD
25 Days
CLINICAL RELEVANCE
THERAPEUTIC AREA
Infectious Disease
ADDITIONAL INFORMATION
BRAND
PDS
TESTING LOCATION
Taiwan - Taipei
OTHER INFORMATION
We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.
ITEM DOES NOT EXIST
© Copyright 2026, Pharmacology Discovery Services – Privacy Policy | Cookie Notice | Cookie Preferences